Shin-Yi Chung*, Yi-Ping Hung*, Yi-Ru Pan, Yu-Chan Chang, Chiao-En Wu, Dennis Shin-Shian Hsu, Peter Mu-Hsin Chang, Meng-Lun Lu, Chi-Ying F Huang, Yeu Su, Michael Hsiao, Chun-Nan Yeh, Ming-Huang Chen. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines 2021 Jul 24;9(8):885 (IF 5.61)

Yi-Ping Hung, Yu-Yun Shao, Chiun Hsu, Chih-Hung Hsu, Jan-Mou Lee, Muh-Hwa Yang, Yee Chao. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. Journal of the Formosan Association. 2020. Online 15 December 2020. (IF: 3.282)

Yi-Ping Hung, Yu-Yun Shao, Chiun Hsu, Chih-Hung Hsu, Jan-Mou Lee, Muh-Hwa Yang, Yee Chao. Potential of Circulating Immune Cells as Biomarkers of Nivolumab Treatment Efficacy for Advanced Hepatocellular Carcinoma. J Chin Med Assoc. 2020. 84(2):144-150. (IF: 2.743)

Yi‐Ru Pan, Chiao‐En Wu, Yu‐Chao Wang, Yi‐Chen Yeh, Meng‐Lun Lu, Yi‐Ping Hung, Yee Chao, Da‐Wei Yeh, Chien‐Hsing Lin, Jason Chia‐Hsun Hsieh, Ming‐Huang Chen, Chun‐Nan Yeh. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clin Transl Immunol. 2020, 9: e1145. (IF: 7.271)

Lu L, -C, Hsu C, Shao Y, -Y, Chao Y, Yen C, -J, Shih I-L, Hung Y, -P, Chang C, -J, Shen Y, -C, Guo J, -C, Liu T, -H, Hsu C, -H, Cheng A, -L: Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer 2019;8:480-490. (IF: 11.740)

Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. J Chin Med Assoc. 2018 Jul;81(7):593-598. (IF: 2.743)

Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, Chen MH. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. Int J Biol Sci. 2016 Nov 25;12(12):1523-1532. (IF: 6.58)